NCT03715504View on ClinicalTrials.gov

Study of TP-3654 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

March 30, 2021

Study Completion Date

July 8, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

TP-3654

oral PIM inhibitor

Trial Locations (3)

22903

University of Virginia, Charlottesville

77030

MD Anderson, Houston

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03715504 - Study of TP-3654 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter